ERBB2 and neoplasm: For example, in subgroup analyses according to tumor subtype (eFigure 6 in Supplement 1), significant decreases in mortality were consistently observed for highest vs lowest LIS among patients with hormone receptor–positive, ERBB2-negative tumors (HR, 0.45; 95% CI, 0.26-0.80), triple-negative BC (HR, 0.47; 95% CI, 0.29-0.76), and ERBB2-positive tumors (HR, 0.25; 95% CI, 0.08-0.76).